Literature DB >> 21076445

Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.

Mark A Perazella1.   

Abstract

Tenofovir, used in combination with other antiretroviral agents, is an effective therapy for HIV infection. Although large clinical studies and post-marketing data support a benign renal profile for tenofovir, numerous cases of kidney injury raise concern for nephrotoxic potential. Early human studies and experimental evidence suggested that tenofovir itself was not associated with mitochondrial toxicity within the kidney. However, recent animal data demonstrate that tenofovir causes mitochondrial DNA depletion and mitochondrial toxicity. Herlitz et al. confirm the nephrotoxicity of tenofovir in humans. They describe its clinical consequences, histopathologic findings, and its mitochondrial toxicity in HIV+ patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21076445     DOI: 10.1038/ki.2010.344

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

1.  Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients.

Authors:  Sirirat Likanonsakul; Tippawan Rattanatham; Siriluk Feangvad; Sumonmal Uttayamakul; Wisit Prasithsirikul; Somkid Srisopha; Ravee Nitiyanontakij; Pimrapat Tengtrakulcharoen; Maciej Tarkowski; Agostino Riva; Emi E Nakayama; Tatsuo Shioda
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-20       Impact factor: 2.205

Review 2.  Cellular and Molecular Mechanisms of AKI.

Authors:  Anupam Agarwal; Zheng Dong; Raymond Harris; Patrick Murray; Samir M Parikh; Mitchell H Rosner; John A Kellum; Claudio Ronco
Journal:  J Am Soc Nephrol       Date:  2016-02-09       Impact factor: 10.121

Review 3.  Pharmacology behind Common Drug Nephrotoxicities.

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

Review 4.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 5.  Risk perception and communication in sub-Saharan Africa.

Authors:  Alexander Dodoo; Bruce Hugman
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

6.  Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study.

Authors:  Mohamad Zaidan; François-Xavier Lescure; Isabelle Brochériou; Sarah Dettwiler; Jean-Baptiste Guiard-Schmid; Jérôme Pacanowski; Eric Rondeau; Gilles Pialoux; Pierre-Marie Girard; Pierre Ronco; Emmanuelle Plaisier
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 8.237

7.  Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.

Authors:  Murli Purswani; Kunjal Patel; Jeffrey B Kopp; George R Seage; Miriam C Chernoff; Rohan Hazra; George K Siberry; Lynne M Mofenson; Gwendolyn B Scott; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

8.  Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis.

Authors:  Reuben Kiggundu; Bozena M Morawski; Nathan C Bahr; Joshua Rhein; Abdu K Musubire; Darlisha A Williams; Mahsa Abassi; Henry W Nabeta; Kathy H Hullsiek; David B Meya; David R Boulware
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

Review 9.  The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.

Authors:  Giuseppe Coppolino; Mariadelina Simeoni; Chiara Summaria; Maria Concetta Postorino; Laura Rivoli; Alessio Strazzulla; Carlo Torti; Giorgio Fuiano
Journal:  J Nephrol       Date:  2015-06-09       Impact factor: 3.902

10.  In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.

Authors:  Lung-Yi Mak; Sze-Hang Liu; Desmond Yat-Hin Yap; Wai-Kay Seto; Danny Ka-Ho Wong; James Fung; Tak-Mao Chan; Ching-Lung Lai; Man-Fung Yuen
Journal:  Dig Dis Sci       Date:  2019-07-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.